Table 1.

Recommended first-Line antiretroviral treatment options.

Committee	Treatment regimens (combinations of agents from column 1 and column 2)		Issues to consider
Department of Health and Human Services, USA1 IAS-USA [Thompson et al. 2010]	(TDF/FTC)	EFV DRV/r ATV/r RAL	3TC/ABC weaker antiretroviral activity in patients with baseline VL > 100,000 ABC: leads to hypersensitivity in carriers of HLA-B*5701 ABC: cardiovascular side effects EFV: avoid in pregnancy, psychiatric side effects
World Health Organization (WHO)2	(ZDV/3TC) or (TDF + (3TC or FTC))	EFV NVP	RAL: low drug interaction potential, twice-daily dosing ATV: cannot be given with acid-lowering drugs ZDV: causes anemia, headaches, fatigue ATV/r, DRV/r, LPV/r: once-daily dosing for first-line treatment
European AIDS Clinical Society (EACS)3	(TDF/FTC) or (3TC/ABC)	EFV NVP ATV/r DRV/r LPV/r SQV/r

TDF, tenofovir; FTC, emtricitabine; EFV, efavirenz; DRV, darunavir; ATV, atazanavir; RAL, raltegravir; NVP, nevirapine; ZDV, zidovudine; 3TC, lamavudine; ABC, abacavir; LPV, lopinavir, SQV, saquinavir; r, low-dose ritonavir; VL, viral load.

¹Available at: http://www.aidsinfo.nih.gov.

²Available at: http://www.who.int/hiv/pub/arv/adult2010/en/index.html.

³Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf.